Sai Life Sciences Limited announced the outcome of its Board Meeting held on November 5, 2026. The board approved the unaudited standalone and consolidated financial results for the second quarter and half year ended September 30, 2026. Additionally, the company approved the allotment of 27,005 and 81,000 fully paid-up equity shares upon exercise of employee stock options. The appointments of new Senior Management Personnel were also confirmed.
Board Meeting Outcomes
Sai Life Sciences Limited convened its Board of Directors meeting on Thursday, November 5, 2026. During the meeting, the board considered and approved several key matters, including the company’s financial performance for the second quarter and the first half of the fiscal year ending September 30, 2026. This includes both standalone and consolidated financial results, accompanied by limited review reports.
Equity Allotment and Share Capital Increase
A significant decision was the approval for the allotment of 27,005 and 81,000 fully paid-up equity shares. These shares were issued upon the exercise of options granted under the company’s Employees Stock Option Plan 2008 (ESOP 2008) and Management Employee Stock Option Plan 2018 (MESOP 2018). This allotment has resulted in an increase in the company’s issued, subscribed, and paid-up equity share capital from ₹21,24,72,716/- to ₹21,25,80,721/-.
Senior Management Appointments
Following the recommendation of the Nomination and Remuneration Committee, the Board of Directors approved the appointment of three individuals to Senior Management Personnel (SMP) positions, effective November 5, 2026:
- Mr. Sidhartha Das as Senior Vice President & Head – Human Resources.
- Mr. Vijay Kumar Suthari as Vice President – Head Quality & Regulatory Affairs.
- Mr. Sriram Gopalakrishnan as Senior Vice President – Corporate Communications.
Detailed profiles and reasons for these appointments are provided in Annexure-A, as required by SEBI Listing Regulations.
Financial Highlights
The unaudited standalone financial results for the six months ended September 30, 2026, show a total income of ₹12,011.90 million and a profit before tax of ₹2,236.42 million. For the same period, the consolidated financial results reported a total income of ₹12,203.82 million and a profit before tax of ₹2,292.54 million.
Auditor’s Review
The standalone and consolidated financial results have been reviewed by Deloitte Haskins & Sells LLP, the statutory auditors of the Company. They have issued an unmodified conclusion on the limited review for the quarter and six months ended September 30, 2026.
Source: BSE
